Accurate Classification of the Gut Microbiota of Patients in Intensive Care Units During the Development of Sepsis and Septic Shock

Wanglin Liu^{1,*,a}, Mingyue Cheng^{2,*,b}, Jinman Li^{3,*,c}, Peng Zhang^{2,d}, Hang Fan^{3,e}, Qinghe Hu^{1,f}, Maozhen Han^{2,g}, Longxiang Su^{1,h}, Huaiwu He^{1,i}, Yigang Tong^{4,*,j}, Kang Ning^{2,*,k}, Yun Long^{1,*,l}

¹ Department of Critical Care Medicine, Peking Union Medical College Hospital, Beijing, China

² Key Laboratory of Molecular Biophysics of the Ministry of Education, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, China

³ State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China

⁴ Beijing Advanced Innovation Center for Soft Matter Science and Engineering (BAIC-SM), College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China

[#] Equal contribution.

^{*} Corresponding authors.

E-mail: tong.yigang@gmail.com (Tong Y), ningkang@hust.edu.cn (Ning K), ly_icu@aliyun.com (Long Y).

Running title: Wanglin Liu et al / Enterotype and ICU Septic Shock

^aORCID: 0000-0002-1090-8325

^bORCID: 0000-0003-1243-5039

29 ^cORCID: 0000-0003-0754-0758

30 ^dORCID: 0000-0002-2912-9698

31 ^eORCID: 0000-0002-7927-1684

32 ^fORCID: 0000-0003-3075-8114

33 ^gORCID: 0000-0002-5958-1941

34 ^hORCID: 0000-0002-0942-2870

35 ⁱORCID: 0000-0001-5104-3340

36 ^jORCID: 0000-0002-8503-8045

37 ^kORCID: 0000-0003-3325-5387

38 ^lORCID: 0000-0003-0274-8322

39

40 Total counts of letters in the article title: 112

41 Total counts of letters in the running title: 42

42 Total counts of keywords: 5

43 Total counts of words in Abstract: 286

44 Total counts of words in main text: 4643

45 Total counts of figures: 3

46 Total counts of tables: 2

47 Total counts of supplementary figures: 4

48 Total counts of supplementary tables: 6

49 Abstract

50 The gut microbiota of intensive care unit (ICU) patients display extreme dysbiosis,
 51 which is associated with increased susceptibility to organ failure, sepsis and septic
 52 shock. However, this dysbiosis is hard to be characterized for each patient, owing to
 53 the highly dimensional complexity of gut microbiota. We thus tested whether the
 54 concept of enterotype can be applied to the gut microbiota of ICU patients, to describe
 55 the dysbiosis. We collected 131 fecal samples from a cohort of 64 ICU patients
 56 diagnosed with sepsis or septic shock, using 16S rRNA gene sequencing to dissect
 57 their gut microbiota compositions. We find that during the development of sepsis or
 58 septic shock, as well as various medical treatments, ICU patients always contain two
 59 patterns of dysbiotic microbiota named as ICU-enterotypes, which cannot be
 60 explained by the individual host properties such as age, gender and body mass index,
 61 as well as external stressors such as infection sites and antibiotic use. ICU-enterotype
 62 I comprised predominantly *Bacteroides* and an unclassified genus of family
 63 *Enterobacteriaceae*, while ICU-enterotype II comprised predominantly *Enterococcus*.
 64 Among more critically ill patients with acute physiology and chronic health
 65 evaluation (APACHE) II score > 18, samples of septic shock were more likely to
 66 present with ICU-enterotype I ($p = 0.041$). Additionally, ICU-enterotype I was
 67 correlated with high serum lactate level ($p = 0.007$). Therefore, different patterns of
 68 dysbiosis are correlated with different clinical outcomes, suggesting that the diagnosis
 69 of ICU-enterotypes as an independent clinical index is crucial. For this purpose, the
 70 microbial-based human index (MHI) classifier we proposed shows high precision and
 71 effectiveness in timely monitoring of ICU-enterotypes of an individual patient.
 72 Together, our work serves as the first step toward precision medicine for septic
 73 patients based on the gut microbiota profile.

74

75 KEYWORDS: Sepsis; Septic shock; Gut microbiota; Enterotype; Precision medicine

76

77 Introduction

78 In intensive care units (ICUs), patients are in critically ill conditions, along with
 79 inflammation and suppression of the immune system. These patients usually undergo
 80 frequent medical interventions including administration of antibiotics, vasoactive
 81 agents, and opioids. Together, these factors can lead to disruption of the gut
 82 microbiota of ICU patients and such dysbiosis may increase susceptibility to
 83 hospital-acquired infections, sepsis and multi-organ dysfunction syndrome in return
 84 [1–3]. Therefore, the gut microbiota should be carefully treated when performing
 85 medical interventions.

86 To date, a number of preliminary studies have investigated the gut microbiota of
 87 ICU patients (shortened as ICU gut microbiota) [4–7]. ICU gut microbiota has been
 88 previously characterized as displaying extreme dysbiosis, with loss of
 89 health-promoting commensal microbes such as those belonging to the phyla
 90 Firmicutes and Bacteroidetes, and an increase of pathogenic microbes such as
 91 Proteobacteria [6]. However, this dysbiosis is hard to be characterized for each patient,
 92 owing to the high heterogeneity of gut microbiota. Thus, it is necessary for
 93 researchers to find a proper way to characterize the ICU gut microbiota, which is
 94 meaningful to clinical diagnosis.

95 Recently, enterotype analysis [8,9] has been applied to a variety of studies
 96 referring to gut microbiota, especially the enterotypes of healthy human gut (termed
 97 as conventional enterotypes). It is interesting that a certain number of studies have
 98 observed two patterns of conventional enterotypes [10,11], in spite of the distinction
 99 of diet, genetic materials and environmental exposure among those studies. Therefore,
 100 we hypothesize that two or more patterns of ICU gut microbiota (termed as
 101 ICU-enterotypes) can be observed in ICU patients, in spite of the distinction of the
 102 inherited traits and external stressors such as the infection types and antibiotic use.

103 In this study, we recruited a cohort of ICU patients with sepsis or septic shock to
 104 confirm our hypothesis, through investigating their gut microbiota composition. We
 105 observed that two patterns of ICU-enterotypes were pervasive during the nine-day

sampling, even though the subjects were of quite heterogeneity in the infection types and antibiotic use. Moreover, we found patients with septic shock were more likely to present with ICU-enterotype I, which also correlated with high serum lactate level. These results might be caused by the microbiota patterns of ICU-enterotype I, which contained dominant unclassified genus of family *Enterobacteriaceae* and *Bacteroides*, compared to ICU-enterotype II which contained predominantly *Enterococcus*. Additionally, the MHI classifier proposed in this study can facilitate timely monitoring of the ICU-enterotypes of patients towards microbiome-based precision medicine.

Results

A cohort of 64 ICU patients (Aged 57.71 ± 18.85) who developed sepsis or septic shock were enrolled in this study. Thirty-two patients received carbapenem administration with or without combination of other types of antibiotics (classified as carbapenem use group), while 30 patients received other types of antibiotics such as cephalosporin, penicillin, azithromycin, fluoroquinolones or vancomycin (classified as non-carbapenem use group). Patients received carbapenem were separated because of its broad-spectrum activity against bacteria and its wide use in critically ill patients [12,13]. The remaining two patients did not use antibiotics during sample collecting duration. We collected 131 fecal samples from these 64 patients during their first nine days in ICU for ICU-enterotype identification. To avoid repeated measures from the same individual, we then used their first fecal samples ($n = 64$) and the corresponding clinical information, such as sequential organ failure assessment (SOFA) score (10.67 ± 4.02), acute physiology and chronic health evaluation (APACHE) II score (20.37 ± 8.14), and lactate level (2.33 ± 2.88), to investigate on the correlation between microbiome compositions and clinical parameters. The antibiotic usage and the detailed clinical information of 64 patients at the day of the collection of their first fecal samples are available in Table S1. The details of the distribution and

characteristics of the 131 fecal samples obtained over the nine days are available in Figure S1 and Table S2.

Two ICU-enterotypes were identified in ICU gut microbiota

Two ICU-enterotypes were identified using the same methods reported in the original paper, with qualified statistical evaluation (Table S3). The distributions of taxa at phylum, class, order, family, genus levels showed significant differences in two ICU-enterotypes (Table S4). The microbial richness (quantified by the number of observed operational taxonomic units (OTUs)) was lower in samples of ICU-enterotype I than samples in ICU-enterotype II ($p = 2.064e-4$, Mann-Whitney-Wilcoxon Test), while the microbial diversity (Shannon index) showed no statistically significant difference ($p = 0.05729$). As shown in **Figure 1A** and **B**, at phylum level, Bacteroidetes were more prevalent in ICU-enterotype I ($p = 3.08607e-14$), while Actinobacteria and Firmicutes were more prevalent in ICU-enterotype II ($p = 6.19996e-10$, $p = 9.24951e-08$, Kruskal-Wallis test, respectively). At genus level, *Bacteroides* and *Parabacteroides* were more prevalent in ICU-enterotype I ($p = 6.65034e-12$, $p = 1.48078e-11$, respectively), while *Enterococcus*, *Vagococcus* and *Lactobacillus* were more prevalent in ICU-enterotype II ($p = 7.51562e-13$, $p = 2.14396e-11$, $p = 0.001992467$, respectively). Importantly, an unclassified genus of the family *Enterobacteriaceae* was quite dominant in ICU-enterotype I (0.251 ± 0.257 in ICU-enterotype I, 0.082 ± 0.0165 in ICU-enterotype II, $p = 9.49e-06$).

As shown in Figure 1C, two most discriminating genera named *Bacteroides* (dominant in ICU-enterotype I) and *Enterococcus* (dominant in ICU-enterotype II), as well as their ratio, showed obvious gradient distributions against the PCo 1 axis. Both these distributions were close to log-normal, suggesting the enrichment of *Bacteroides* in ICU-enterotype I and *Enterococcus* in ICU-enterotype II. These results indicate that, unlike the conventional enterotypes characterized by distributions of *Bacteroides* and *Prevotella* [8], ICU-enterotypes largely depend on the distributions of *Bacteroides* and

161 *Enterococcus*. Moreover, the gradient distributions of the unclassified genus of the
162 family *Enterobacteriaceae* was observed against PCo 2 axis (Figure S2). Considering
163 its dominant abundance in ICU-enterotype I and potential pathogenicity, its identity
164 deserves further investigations.

165 We found that the pathogens identified from positive bacterial culture tests of the
166 infection sites of patients partially overlapped with the gut microbiome profiles at
167 genus level (Table S1, Table S4). Most of the overlapped genera such as *Enterococcus*,
168 *Staphylococcus*, *Corynebacterium* and *Acinetobacter* were observed differently
169 distributed between two ICU-enterotypes. It confirmed the associations between gut
170 microbiome and causative pathogens outside the intestine.

171 **ICU-enterotypes are pervasive in the cohort of ICU patients**

172 The two identified ICU-enterotypes are pervasive in the cohort of ICU patients with
173 sepsis and septic shock. As was shown in Figure 1D, the samples of admission mixed
174 within all samples collected during ICU days, without any clustering pattern.
175 Additionally, they were also distributed among two ICU-enterotypes. We then
176 displayed the distributions of all 131 samples on each of nine days to test whether the
177 enterotypes remained when using one single sample of different patients (Figure 1F).
178 Interestingly, the ICU-enterotypes were observed obvious on each day, in spite of the
179 differences in the subject sets and the proportion of various antibiotic categories on
180 each day. We also found that the distribution of carbapenem use before or after ICU
181 admission (Figure S3A and B) showed no significant difference in ICU-enterotypes
182 (Mann-Whitney-Wilcoxon test). The distribution of infection sites was observed to
183 correlate with ICU-enterotype: Samples of non-pulmonary infection enriched in the
184 ICU-enterotype I (Figure S3D). This correlation still needs further validation on a
185 larger scale. We did not deny that the antibiotics and infection types can impact on gut
186 microbiota of ICU patients, however, they were not the determinants of
187 ICU-enterotypes. ICU-enterotypes might be two resulted patterns of the dysbiosis of
188 ICU gut microbiota, caused by intricate factors such as inherited traits, various

189 medical treatments and infection types of ICU patients.

190 The stability of ICU-enterotypes of individual patients during the first nine days
191 remained unknown, owing to the lack of samples at several time points.
192 ICU-enterotype variation was observed in 14 patients (Figure S1), while no change of
193 ICU-enterotypes were observed for the remaining patients, which was probably due to
194 the small sample size. Notably, ICU-enterotype of a patient (with ID 2167789) was
195 observed quite stable, even on a continuous sampling of five days (Figure 1E). The
196 stability of ICU-enterotypes might be less than the conventional enterotypes, on
197 account of that the ICU patients were frequently exposed to various external stressors
198 that would largely affect the gut microbiota. Considering the relative instability of
199 ICU-enterotypes and their correlation with septic shock observed in the following
200 sections, it is important to realize the timely monitoring of ICU-enterotypes of
201 patients.

202 **Highly effective binary classifier for discriminating ICU-enterotypes**

203 Identifying the ICU-enterotype of a single sample can facilitate the timely monitoring
204 of ICU-enterotypes. Thus, we proposed a binary classifier for this intention, based on
205 the non-redundant taxonomic biomarkers of ICU-enterotypes, selected by LEfSe and
206 mRMR. As shown in **Figure 2A** and **B**, ten selected taxonomic biomarkers at different
207 phylogenetic levels were of great discriminant ability with LDA scores ($\log_{10}$) > 4.0 ,
208 as well as of large differences in abundance proportion in two ICU-enterotypes.
209 Additionally, Bacteroidetes, Firmicutes at phylum level, and *Bacteroides*,
210 *Enterococcus* at genus level were the most discriminant biomarkers.

211 We then combined these ten biomarkers to produce MHI score of each fecal
212 sample, as described in the methods section. We firstly compared the ability of the
213 relative abundance of each individual biomarker and the MHI score, to classify all
214 131 samples into two ICU-enterotypes (Figure 2C and D, Figure S4). The results
215 showed that the microbial-based human index (MHI) score improved effectiveness of
216 classifying these samples into ICU-enterotype I or II, with the highest area under the

curve (AUC) value of 0.9791 (95% CI: 0.9586–0.9997) compared with any individual taxonomic biomarker.

We then proposed a threshold of MHI score as the judgment criteria of the MHI classifier for convenient clinical diagnosis. The threshold was trained to 1.017 in the training set of 106 samples and then applied to the testing set of 25 samples. As shown in **Table 1**, the classifier with this trained threshold (1.017) showed an AUC of 0.982 and an F1 score of 0.929 during the training process. Moreover, this classifier was effective for classification during the testing process as well, with an AUC of 0.985 and an F1 score of 0.903. Taken together, these results indicate that the combination of these ten taxonomic biomarkers as the MHI score has the potential to serve as an effective classification strategy for assessing ICU-enterotypes in ICU clinical trial. Its practical performance on other septic cohort in ICU clinical trials still needs further evaluation.

Two ICU-enterotypes are correlated with septic shock and serum lactate

Correlation with septic shock

The ICU-enterotypes were observed to correlate with septic shock. As shown in Figure 1D and **Table 2**, the samples of sepsis (106 samples from 46 patients) were highly prevalent in both ICU-enterotype I (69 samples from 33 patients, 65.1%) and ICU-enterotype II (37 samples from 13 patients, 34.9%). However, the samples of septic shock (25 samples from 18 patients) were mostly classified as ICU-enterotype I (20 samples from 14 patients, 80%), with a small number classified as ICU-enterotype II (five samples from four patients, 20%). Considering the microbiome compositions and clinical conditions (such as the status of sepsis or septic shock and APACHE II score) of each sample varied every day under clinical intervention, we then viewed these samples as independent. Higher APACHE II score indicates severer disease condition [14–16] and we found that in this study, patients who did not survive had higher APACHE II score than those who survived (median $\pm$ interquartile range: 18.5 $\pm$ 11 versus 22.5 $\pm$ 14, $p = 0.1$, Mann–Whitney–Wilcoxon test), though

245 non-statistically significant. We thus set a cutoff value for APACHE II score as > 18
 246 to decide whether samples are from patients with severer disease conditions. Among
 247 samples with an APACHE II score > 18 (83 out of 131 samples), a significantly larger
 248 proportion (86.7% vs. 57.4%, $p = 0.041$, Fisher's exact test) of samples of septic
 249 shock presented with ICU-enterotype I than that of samples of sepsis. Nevertheless,
 250 among samples with an APACHE II score ≤ 18 , no significant difference ($p = 0.675$)
 251 between sepsis and septic shock was observed. These results indicate that patients
 252 with septic shock are more likely to present with ICU-enterotype I, especially in the
 253 case of a more critical status.

254

255 *Correlation with serum lactate*

256 To seek for the correlations between ICU-enterotypes and clinical parameters, we
 257 used a subset of 64 samples (one sample per patient) so that the influence of
 258 heterogeneity in sample size of patients can be eliminated. These 64 samples were
 259 composed of the first collected sample of each patient, whose enterotypes were
 260 designated according to enterotype analysis in the former sections. Additionally, the
 261 clinical parameters were recorded at the same day with the collection of fecal samples
 262 (Table S1). As shown in Table S5, no significant difference was observed in the
 263 distribution of sex ($p = 0.4$), age ($p = 0.68$), collecting day of samples ($p = 0.7323$),
 264 carbapenem use ($p = 0.57$), breath support ($p = 0.73$) between two ICU-enterotypes,
 265 indicating that there was no selection bias of samples between two ICU-enterotypes.
 266 We then tested whether crucial clinical parameters, generally used to evaluate the
 267 severity of disease condition for septic patients, were different between the two
 268 ICU-enterotypes. No significant difference was observed in the SOFA score ($p = 0.8$),
 269 APACHE II score ($p = 0.474$), 28-day survival ($p = 0.36$) between the two
 270 ICU-enterotypes (Table S5). Interestingly, patients of ICU-enterotype I tended to have
 271 higher levels of serum lactate than patients of ICU-enterotype II, though the
 272 difference was not significant (2.66 ± 3.30 vs. 1.42 ± 0.52 , $p = 0.07$). We then divided
 273 the patients into high lactate (serum lactate ≥ 2.5 mmol/L) and low lactate (serum
 274 lactate < 2.5 mmol/L) groups. As shown in **Figure 3A**, all of the patients in the high

lactate group presented with ICU-enterotype I, and only a certain number of patients in the low lactate group presented with ICU-enterotype II ($p = 0.007$). It turned out that ICU-enterotype I correlated with high serum lactate level.

We subsequently performed Mantel test [17] on these 64 samples to test whether clinical parameters of patients can explain gut microbiota variation within ICU-enterotypes. As shown in Figure 3B, the clinical parameters correlated with each other, making them able to cooperatively indicate the severity of illness. Only a few clinical parameters were observed to be able to explain parts of gut microbiota variation (Figure 3B and Table S6. The microbiota variation of ICU-enterotype I was observed to positively correlate with serum lactate concentration ($r = 0.148$, $p = 0.0481$), suggesting that patients of ICU-enterotype I tended to have more diversified gut microbiota patterns if they have more different serum lactate levels. However, this correlation was not observed in patients with ICU-enterotype II ($r = -0.079$, $p = 0.815$).

Discussion

During the period of development of sepsis or septic shock, as well as various medical treatments, ICU patients were observed to contain two quite distinct patterns of gut microbiota, designated as ICU-enterotypes. ICU-enterotypes cannot be explained by the individual host properties such as age, gender and body mass index, as well as external stressors such as infection sites and antibiotic usage. Although the causes of ICU-enterotypes remain unknown, their prevalence, as well as correlation with septic shock and serum lactate level makes them pragmatic for clinical trial, as an independent clinical parameter referring to gut microbiota.

ICU gut microbiota have been previously described as displaying extreme dysbiosis, with loss of health-promoting bacteria and growth of pathogenic bacteria. However, the two ICU-enterotypes identified here indicate that this dysbiosis contains two quite distinct patterns with corresponding sets of loss or growth of bacteria. For example, a loss of *Bacteroides* but a growth of *Enterococcus* was observed in

ICU-enterotype II, while the result is diametrically opposite in ICU-enterotype I. Moreover, the bacteria differently distributed between two ICU-enterotypes were observed to partially overlap with the causative pathogens at genus level outside the intestine. Therefore, the dysbiosis of ICU gut microbiota should be analyzed and treated with different strategies according to ICU-enterotypes.

Despite that both ICU-enterotypes are of extreme dysbiosis, their different microbiota patterns correlate with different outcomes. For instance, the larger ratio of *Bacteroides* to *Firmicutes* in ICU-enterotype I, whose ratio > 10 was reported to be correlated with a higher death rate in ICU patients [5], may reflect a critical status of patients. In addition, an unclassified genus of family *Enterobacteriaceae* was observed quite dominant in ICU-enterotype I. Considering the fact that another classified member of this family, named *Enterobacter*, can cause a wide variety of nosocomial infections such as neonatal sepsis with meningitis [18], the identity and potential pathogenicity of this unclassified genus deserve further investigations. On the other hand, *Enterococcus*, which might cause urinary tract infections, abdominal-pelvic infections and endocarditis [19–21], was observed dominant in ICU-enterotype II. Nevertheless, *Enterococcus* was reported to play a role in enhancing immunity and inhibiting overgrowth of opportunistic pathogens, by enhancing the production of short chain fatty acids [22,23] and bacteriocins [24–26]. From this point of view, the overgrowth of *Enterococcus* in ICU-enterotype II might be associated with the lower occurrence of septic shock in ICU-enterotype II through these effects. However, more studies are need to test this speculation. Taken together, both ICU-enterotypes have the potential to lead to sever pathogenic diseases, while the difference in clinical outcome would link to the different patterns of dysbiosis of ICU-enterotypes such as the higher correlation between ICU-enterotype I and septic shock. Moreover, considering the existence of this link, the MHI classifier proposed in this study may facilitate the timely monitoring of ICU-enterotypes variation of patients. The MHI classifier stresses on the improved classification ability of combination of biomarkers, as compared with single biomarker. We believe this strategy can improve the microbiome classification of the other cohort.

ICU-enterotypes can not only serve as an independent clinical parameter for characterization of ICU gut microbiota but also indicate disease severity. In this study, our samples from severe disease conditions showed correlation between ICU-enterotype I and septic shock. In addition, ICU-enterotype I was observed to correlate with high levels of serum lactate, suggesting deterioration of critical hemodynamics. Elevated serum lactate reflects increased anaerobic glycolysis, and is commonly considered to be a marker of tissue hypoxia or hypoperfusion in critically ill patients [27–30]. A certain number of studies suggested that serum lactate > 2mmol/L was independently correlated with mortality in both shock and non-shock patients [30]. Other studies argued that a blood lactate concentration > 0.75mmol/L was independently correlated with increased mortality [31]. In spite of the dispute over the cutoff value, the higher the lactate level, the greater the risk of death, and treatments guided by lactate levels have achieved decreased mortality [32]. Therefore, the ICU-enterotypes have the potential to be the markers of disease severity, thus guiding clinical interventions.

This study also has limitations. Firstly, the lack of healthy subjects and ICU patients without sepsis or septic shock. Secondly, the lack of fecal samples at a certain number of time points restricted us to trace the evolution of ICU-enterotypes in individual patients and to investigate the predictive ability of ICU-enterotypes for developing sepsis or septic shock. Thirdly, the relatively small cohort of our study may have limited the statistical power of the results. Moreover, owing to the lack of detailed clinical information in other studies, we cannot perform a reasonable comparison analysis in other cohorts, though such analysis would undoubtedly be of great interests. Lastly, the comorbidities of the subjects were not considered because of the heterogeneity of the enrolled subjects. Nevertheless, all of the intricate factors such as variety of diseases and medical treatments can be viewed as the causes of the dysbiosis. The impacts of these factors on gut microbiota might be quite different, however, all of these cooperatively resulted in two ICU-enterotypes. This study mainly underscores the existence of two ICU-enterotypes among the cohort of ICU patients with sepsis or septic shock.

363 **Conclusions**

364 Despite the fact that ICU gut microbiota are of different dysbiosis, two patterns of this
 365 dysbiosis are observed quite pervasive among the cohort of ICU patients, designated
 366 as ICU-enterotypes. ICU-enterotype I reflects more severe status of septic shock and
 367 correlates with deterioration of critical hemodynamics, suggesting higher level of
 368 critical treatment. Furthermore, it would be worthwhile to investigate how universal
 369 the ICU-enterotypes are among ICU populations around the globe. Better
 370 understanding of this can undoubtedly help for more general practical guide for ICU
 371 clinical treatment.

372 **Materials and methods**

373 **Subjects and clinical assessments**

374 This study was conducted in the Critical Care Department of Peking Union Medical
 375 College Hospital (PUMCH) of China, which is a tertiary referral hospital with 30 beds
 376 in the Critical Care Department. Written informed consent was obtained from all
 377 subjects or their legal representatives. Ethical approval was received from the Medical
 378 Ethics Committee of PUMCH (ethical reference number HS-1350), and all research
 379 was conducted in accordance with the declaration of Helsinki. ICU patients with
 380 sepsis or septic shock, who were either directly admitted to the ICU or transferred to
 381 the ICU from a hospital ward were enrolled in our study from February 2016 to
 382 February 2017. The sequential organ failure assessment (SOFA) score and the acute
 383 physiology and chronic health evaluation (APACHE) II score were calculated on a
 384 daily basis. Sepsis was defined as when a patient was treated with systemic
 385 therapeutic administration of antibiotics due to suspected infection, accompanied by
 386 an increase in SOFA score of 2 points or more [33]. Septic shock was identified by a
 387 vasopressor requirement to maintain a mean arterial pressure of 65 mmHg or greater
 388 and a serum lactate level greater than 2 mmol/L (> 18 mg/dL) in the absence of
 389 hypovolemia [33]. Other clinical assessments including physiologic parameters,

390 serum lactate levels and blood tests results were obtained for each patient on a daily
391 basis. Antibiotic usage, the site of infection, the pathogens from positive bacterial
392 cultures, the duration of ICU stay, the occurrence of mechanical ventilation and 28
393 days survival rate were also collected for each patient.

394 **Fecal sample collection and 16S rRNA gene sequencing**

395 In this study, the included patients were observed for their first nine consecutive days
396 in ICU (starting from the admission day). Fresh fecal samples were collected from
397 each patient either through defecation or enema for patients with constipation. Enema
398 was performed by the nurses using glycerin enema according to the instructions given
399 by the intensivists. If the patient produced multiple fecal specimens at the same day,
400 only one was collected for test. If the patient was not able to produce fecal specimen
401 on some of the days during the observation duration, then no fecal sample will be
402 available for those days. The fresh fecal samples were then immediately frozen at
403 -80°C . Total bacterial DNA was subsequently extracted from homogenized fecal
404 samples using the QIAamp[®] Fast DNA Stool Mini kit (QIAGEN, Cat. No. 51604,
405 Germany) according to the manufacturer's protocol without modification. The V3/V4
406 hypervariable regions of the 16S ribosomal RNA gene were sequenced using the
407 Illumina MiSeq platform. Mothur [34] was used to merge paired-end reads and trim
408 the reads to meet following quality standard: a quality Phred score $\geq$ Q20, no
409 ambiguous bases, homo-polymers shorter than 8 bp, and a read length of 300–500 bp.
410 These trimmed reads were then aligned against SILVA 132 reference files
411 (Silva-based alignment of template file for chimera. slayer, release 132) to identify
412 chimeras. Identified chimers were then removed using the UCHIME algorithm [35].
413 The remaining high-quality sequences were clustered into operational taxonomic units
414 (OTUs) at a 97% sequence identity threshold using UCLUST [36]. The most
415 abundant reads from each of the OTU clusters were taxonomically identified using
416 RDP classifier [37], only accepting annotations with at least 80% confidence.
417 Rarefaction was set at 4000 reads based on curve plateaus for alpha diversity.

418 **Identification of ICU-enterotypes**

419 The relative abundances of OTUs up to the genus level for each sample were used to
 420 perform enterotype analysis [9]. Firstly, the Jensen–Shannon distance (JSD) between
 421 each sample was calculated to produce a JSD matrix using relative abundances at
 422 genus level. Secondly, the partitioning around medoids (PAM) clustering algorithm
 423 was performed on this distance matrix to cluster samples, using the
 424 Calinski–Harabasz (CH) index [38] to assess the optimal number of clusters. Thirdly,
 425 Silhouette coefficients (SI) [39] were calculated to evaluate the statistical significance
 426 of clustering. We set and evaluated the number of clusters from zero to ten, and found
 427 two clusters were of the highest CH and SI. The two classified clusters were then
 428 named ICU-enterotype I and ICU-enterotype II, respectively. The PAM clustering
 429 algorithm, calculation of the CH index and the silhouette index are available in the R
 430 packages ‘cluster’ (version 2.0.7) and ‘clusterSim’ (version 0.47-1).

431 Visualization of the two identified ICU-enterotypes was performed using principal
 432 coordinate analysis (PCoA) by the R packages ‘ade4’ (version 1.7-11) and ‘ggplot2’
 433 (version 2.2.1). All fecal samples were projected onto the two-dimensional plane
 434 using PCo1 and PCo2 as the most discriminant axes. Shaded ellipses were used to
 435 represent the 80% confidence interval, while the dotted ellipse borders indicate the 95%
 436 confidence interval, thus wrapping the samples within an enterotype.

437 **The detection of taxonomic biomarkers of ICU-enterotypes**

438 Taxonomic biomarkers of two identified ICU-enterotypes were firstly picked from the
 439 taxonomic abundance table using linear discriminate analysis (LDA) effect size
 440 (LEfSe) [40]. These selected biomarkers with LDA scores ($\log_{10}$) > 2.0 were then
 441 used as the input for minimum redundancy maximum relevance feature selection
 442 (mRMR) [41] to determine the five non-redundant taxonomic biomarkers of each of
 443 the two ICU-enterotypes.

444 **MHI classifier for discriminating ICU-enterotypes**

445 The microbial-based human index (MHI) was employed to determine the combined
446 effects of the taxonomic biomarkers for discriminating ICU-enterotypes. For each
447 sample, ten taxonomic biomarkers, selected by mRMR as described above, were
448 organized according to the formula below to produce the MHI:

$$449 \quad \text{MHI score} = \frac{\sum_{i=1}^n ABU_r(S_i)}{\sum_{j=1}^m ABU_r(S_j)}$$

450 The numerator was the sum of the relative abundance (ABU_r) of five selected
451 taxonomic biomarkers (S_i) of ICU-enterotype I. The denominator was the sum of the
452 relative abundance of five selected biomarkers (S_j) of ICU-enterotype II. The receiver
453 operating characteristic (ROC) curve with 95% confidence intervals and area under
454 the curve (AUC) with 95% confidence intervals were generated for the 131 samples
455 using 9999 stratified bootstrap replicates, to compare the classification ability of the
456 ten individual taxonomic biomarkers and the MHI score.

457 A threshold was then proposed as the judgment criteria for classifying
458 ICU-enterotypes, i.e., a sample with a MHI score greater than this threshold was
459 classified as ICU-enterotype I and a sample with a MHI score less than this threshold
460 was classified as ICU-enterotype II. The 131 samples were randomly divided into the
461 training set (106 samples, 80%) and the testing set (25 samples, 20%). During the
462 process of training, the threshold was initially set at the min MHI score among
463 samples of training set, and then increased by the value of (the max MHI score – the
464 min MHI score) / 1,000 at every step. This process would terminate when sensitivity
465 and specificity of classification reached to the local optimal value. During the process
466 of testing, the trained threshold was then used to classify the testing set to evaluate the
467 effectiveness of the MHI classifier.

468 **Data availability**

469 The 16S rRNA gene sequencing data are available in the Genome Sequence Archive
470 (GSA) section of National Genomics Data Center (project accession number

471 CRA002354). The codes for selection of taxonomic biomarkers and building of MHI
472 classifier were available in GitHub
473 (<https://github.com/HUST-NingKang-Lab/MH-E-I>).

474 **Authors' contributions**

475 YT, KN, YL designed and supervised the study. QH, LS, HH collected samples and
476 recorded clinical information. JL and HF conducted sequencing. WL, MC, PZ, MH
477 performed data analysis. WL, MC wrote the manuscript with input from all authors.
478 YT, KN, YL reviewed and revised the manuscript.

479 **Competing interests**

480 The authors have declared no competing interests.

481 **Acknowledgments**

482 This work was partially supported by special Fund for Clinical Research of Wu
483 Jieping Medical Foundation (320.6750.18422), Ministry of Science and Technology
484 of the People's Republic of China (2018YFC0910502), National Natural Science
485 Foundation of China (31871334 and 31671374). We thank Qiaorong Wang from
486 Nutricia Pharmaceutical Wuxi Co., Ltd for logistic support in the sample collection
487 and sequencing process.

488

489 **References**

- 490 [1] Alverdy JC, Chang EB. The re-emerging role of the intestinal microflora in
491 critical illness and inflammation: why the gut hypothesis of sepsis syndrome will not
492 go away. *J Leukoc Biol* 2008;83:461–6.
- 493 [2] Latorre M, Krishnareddy S, Freedberg DE. Microbiome as mediator: Do systemic
494 infections start in the gut? *World J Gastroenterol* 2015;21:10487.
- 495 [3] Klingensmith NJ, Coopersmith CM. The gut as the motor of multiple organ
496 dysfunction in critical illness. *Crit Care Clin* 2016;32:203–12.
- 497 [4] Zaborin A, Smith D, Garfield K, Quensen J, Shakhsher B, Kade M, et al.
498 Metagenomic analysis reveals dynamic changes of whole gut microbiota in the acute
499 phase of intensive care unit patients. *mBio* 2014;5:e01361–14.
- 500 [5] Ojima M, Motooka D, Shimizu K, Gotoh K, Shintani A, Yoshiya K, et al.
501 Metagenomic analysis reveals dynamic changes of whole gut microbiota in the acute
502 phase of intensive care unit patients. *Dig Dis Sci* 2016;61:1628–34.
- 503 [6] McDonald D, Ackermann G, Khailova L, Baird C, Heyland D, Kozar R, et al.
504 Extreme dysbiosis of the microbiome in critical illness. *mSphere* 2016;1.
- 505 [7] Lankelma JM, van Vught LA, Belzer C, Schultz MJ, van der Poll T, de Vos WM,
506 et al. Critically ill patients demonstrate large interpersonal variation in intestinal
507 microbiota dysregulation: a pilot study. *Intensive Care Med* 2017;43:59–68.
- 508 [8] Costea PI, Hildebrand F, Manimozhiyan A, Bäckhed F, Blaser MJ, Bushman FD,
509 et al. Enterotypes in the landscape of gut microbial community composition. *Nat*
510 *Microbiol* 2018;3:8
- 511 [9] Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al.
512 Enterotypes in the landscape of gut microbial community composition. *Nature*
513 2011;473:174–80.
- 514 [10] Lim MY, Rho M, Song YM, Lee K, Sung J, Ko G. Stability of gut enterotypes in
515 Korean monozygotic twins and their association with biomarkers and diet. *Sci Rep*
516 2014;4:7348.
- 517 [11] Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, et al.

518 Linking long-term dietary patterns with gut microbial enterotypes. *Science* 2011, 334:
519 105–8.

520 [12]Ruppe E, Burdet C, Grall N, de Lastours V, Lescure FX, Andreumont A, et al.
521 Impact of antibiotics on the intestinal microbiota needs to be re-defined to optimize
522 antibiotic usage. *Clin Microbiol Infect* 2018;24:3–5.

523 [13] Patrier J, Timsit J-F. Carbapenem use in critically ill patients. *Curr Opin Infect*
524 *Dis* 2020;33:86–91.

525 [14] Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of
526 disease classification system. *Crit Care Med* 1985;13:818–29.

527 [15]Giangiuliani G, Mancini A, Gui D. Validation of a severity of illness score
528 (APACHE II) in a surgical intensive care unit. *Intensive Care Med* 1989;15:519–22.

529 [16]Giamarellos-Bourboulis EJ, Norrby-Teglund A, Mylona V, Savva A, Tsangaris I,
530 Dimopoulou I, et al. Risk assessment in sepsis: a new prognostication rule by
531 APACHE II score and serum soluble urokinase plasminogen activator receptor. *Crit*
532 *Care* 2012;16:R149.

533 [17] Mantel N. The detection of disease clustering and a generalized regression
534 approach. *Cancer Res* 1967;27:209–20.

535 [18] Bar-Oz B, Preminger A, Peleg O, Block C, Arad I. *Enterobacter sakazakii*
536 infection in the newborn. *Acta Paediatr* 2001;90:356–8.

537 [19] Fisher K, Phillips C. The ecology, epidemiology and virulence of *Enterococcus*.
538 *Microbiology* 2009;155:1749–57.

539 [20] Ryan KJ, Ray CG. *Medical microbiology*. McGraw Hill 2004;4:370.

540 [21] Gilmore MS, Ferretti JJ. The thin line between gut commensal and pathogen.
541 *Science* 2003;299:1999–2002.

542 [22] Zhao L, Zhang F, Ding X, Wu G, Lam YY, Wang X, et al. Gut bacteria
543 selectively promoted by dietary fibers alleviate type 2 diabetes. *Science*
544 2018;359:1151–6.

545 [23] Wang L, Zhang J, Guo Z, Kwok L, Ma C, Zhang W, et al. Effect of oral
546 consumption of probiotic *Lactobacillus planatarum* P-8 on fecal microbiota, SIgA,
547 SCFAs, and TBAs of adults of different ages. *Nutrition* 2014;30:776–83.

548 [24] Brandao A, Almeida T, Munoz-Atienza E, Torres C, Igrejas G, Hernandez PE, et
549 al. Antimicrobial activity and occurrence of bacteriocin structural genes in
550 *Enterococcus spp.* of human and animal origin isolated in Portugal. Arch Microbiol
551 2010;192:927–36.

552 [25] Escamilla-Martinez EE, Cisneros YMA, Fernandez FJ, Quirasco-Baruch M,
553 Ponce-Alquicira E. Identification of structural and immunity genes of a class IIb
554 bacteriocin encoded in the enterocin A operon of *Enterococcus faecium* Strain
555 MXVK29. J Food Prot 2017;1851–56.

556 [26] Vasilchenko AS, Vasilchenko AV, Valyshev AV, Rogozhin EA. A novel
557 high-molecular-mass bacteriocin produced by *Enterococcus faecium*: biochemical
558 features and mode of action. Probiotics Antimicrob Proteins 2018;10:427–34.

559 [27] Kushimoto S, Akaishi S, Sato T, Nomura R, Fujita M, Kudo D, et al. Lactate, a
560 useful marker for disease mortality and severity but an unreliable marker of tissue
561 hypoxia/hypoperfusion in critically ill patients. Acute Med Surg 2016;3:293–7.

562 [28] Husain FA, Martin MJ, Mullenix PS, Steele SR, Elliott DC. Serum lactate and
563 base deficit as predictors of mortality and morbidity. Am J Surg 2003;185:485–91.

564 [29] Shapiro NI, Howell MD, Talmor D, Nathanson LA, Lisbon A, Wolfe RE, et al:
565 Serum lactate as a predictor of mortality in emergency department patients with
566 infection. Ann Emerg Med 2005;45:524–8.

567 [30] Mikkelsen ME, Miltiades An Fau-Gaieski DF, Gaieski Df Fau -Goyal M, Goyal
568 M Fau-Fuchs BD, Fuchs Bd Fau-Shah CV, Shah Cv Fau-Bellamy SL, et al. Serum
569 lactate is associated with mortality in severe sepsis independent of organ failure and
570 shock. Crit Care Med 2009;37:1670–7.

571 [31] Nichol AD, Egi M, Pettila V, Bellomo R, French C, Hart G, et al. Relative
572 hyperlactatemia and hospital mortality in critically ill patients: a retrospective
573 multi-centre study. Critical Care 2010;14:R25.

574 [32] Kraut JA, Madias NE. Lactic acidosis. N Engl J Med 2014;371:2309–19.

575 [33] Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M,
576 et al. The third international consensus definitions for sepsis and septic shock
577 (sepsis-3). JAMA 2016;315:801–10.

- 578 [34] Schloss PD, Westcott SL, Ryabin T, Hall JR, Hartmann M, Hollister EB, et al.
579 Introducing mothur: open-source, platform-independent, community-supported
580 software for describing and comparing microbial communities. Appl Environ
581 Microbiol 2009;75:7537–41.
- 582 [35] Edgar RC, Haas BJ, Clemente JC, Quince C, Knight R. UCHIME improves
583 sensitivity and speed of chimera detection. Bioinformatics 2011;27:2194–200.
- 584 [36] Edgar RC. Search and clustering orders of magnitude faster than BLAST.
585 Bioinformatics 2010;26:2460–1.
- 586 [37] Wang Q, Garrity GM, Tiedje JM, Cole JR. Naive Bayesian classifier for rapid
587 assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ
588 Microbiol 2007;73:5261–7.
- 589 [38] Caliński T, Harabasz J. A dendrite method for cluster analysis. Commun Stat
590 Theory Methods 1974;3:1–27.
- 591 [39] Rousseeuw PJ. Silhouettes: a graphical aid to the interpretation and validation of
592 cluster analysis. J Comput Appl Math 1987;20:53–65.
- 593 [40] Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, et al.
594 Metagenomic biomarker discovery and explanation. Genome Biol 2011;12:R60.
- 595 [41] Peng H, Long F, Ding C. Feature selection based on mutual information: criteria
596 of max-dependency, max-relevance, and min-redundancy. IEEE Trans Pattern Anal
597 Mach Intell 2005;27:1226–38.

598 **Figures legends**

599 **Figure 1 Two ICU-enterotypes are identified in ICU patients with sepsis and** 600 **septic shock**

601 **A and B.** Taxonomic composition of 131 fecal samples at phylum (**A**) and genus (**B**)
602 level. Taxa whose relative abundance > 1% among all samples are plotted.
603 Unclassified genera are designated as a higher rank marked by asterisks. The left
604 panel represents the taxonomic composition of each sample, while the right panel
605 represents the taxonomic composition of two ICU-enterotypes using mean abundance

606 calculated from the data in left panel. The brown and green bars represent the
607 ICU-enterotypes to which these samples belong. **C.** Distributions of the
608 log-transformed (log10) relative abundance of the most significantly differing genera.
609 The left panel displays the observed distributions using frequency distribution
610 histogram with density curve. The right panel displays these distributions in
611 ICU-enterotype space represented by Jensen–Shannon distance (JSD)-based principal
612 coordinate analysis plot (PCoA) plot. The solid circles refer to samples of septic
613 shock, while the hollow circles refer to samples of sepsis. Color in PCoA plot:
614 log-transformed (log10) relative abundances of the genera for each sample. **D.** Gut
615 microbiota compositions of individual patients in ICU-enterotype I (n = 89) and
616 ICU-enterotype II (n= 42) are plotted on a JSD-based PCoA plot at genus level.
617 Shaded ellipses represent the 80% confidence interval, while the dotted ellipse
618 borders represent the 95% confidence interval. **E.** The variation of ICU-enterotypes of
619 five individual patients (with their ID shown at the top) along the nine-day
620 observation. Results for other patients are shown in Figure S1. **F.** In the left panel, the
621 distributions of fecal samples on each day are plotted against the PCo1 axis of (D).
622 Boxes represent the interquartile range (IQR) between first and third quartiles and the
623 line inside represents the median. Whiskers denote the lowest and highest values
624 within $1.5 \times \text{IQR}$ from the first and third quartiles, respectively. In the right panel, the
625 proportions of antibiotics used on each day are displayed using all samples, samples
626 of ICU-enterotype I, ICU-enterotype II, respectively.

627

628 **Figure 2 MHI score shows greater discriminant ability than single taxonomic**
629 **biomarker in ICU-enterotypes classification**

630 **A.** Ten taxonomic biomarkers selected by LEfSe and mRMR are shown with the
631 length of the bar representing the LDA score (log10) and the color indicating which
632 ICU-enterotypes these biomarkers belong to. **B.** The relative abundances of the most
633 dominant biomarkers at phylum and genus level differ largely between two
634 ICU-enterotypes. Boxes represent the interquartile range (IQR) between first and third
635 quartiles and the line inside represents the median. Whiskers denote the lowest and

highest values within $1.5 \times \text{IQR}$ from the first and third quartiles, respectively. Statistical significance is tested using the Mann–Whitney–Wilcoxon test, $***P < 0.001$, n.s., not significant. **C. The receiver operating characteristic (ROC)** is performed for all 131 samples using 10 individual taxonomic biomarkers or the **microbial-based human index (MHI)** score. ROC with 95% **confident interval (CI)** of each biomarker or MHI score is displayed in Figure S4. **D.** AUC with 95% CI calculated from the results of (C).

Figure 3 Two ICU-enterotypes are correlated with different clinical parameters

A. The pie charts show proportions of patients of two ICU-enterotypes in high lactate group (left panel), as well as low lactate group (right panel). Fisher’s exact test is used to evaluate the statistical significance of the difference in these proportions. **B.** The correlation matrix is produced using Pearson correlation coefficients between each pair of Z-scores-transformed clinical parameters. The size and the color of the circles refer to the strength of these Pearson correlations coefficients, as shown in the bottom of the matrix. The correlations between taxonomic composition of ICU-enterotypes and each of Z-scores-transformed clinical parameters are calculated using Mantel test. Samples of ICU-enterotype I and ICU-enterotype II are tested respectively. The colors of lines refer to the Mantel statistical significance. The solid line refers to positive correlation, while the dashed line refers to negative correlation. The full names of clinical parameters and detailed values of Mantel test are shown in Table S6.

Tables

Table 1 Evaluation of the classification ability of MHI classifier

Sample set	Accuracy	Sensitivity	Specificity	AUC	Precision	Recall	F1 Score
Training	0.906	0.903	0.912	0.982	0.956	0.903	0.929
Testing	0.880	0.824	1.000	0.985	1.000	0.824	0.903

661

662 **Table 2 Distributions of ICU-enterotypes differ between patients with sepsis**
663 **and septic shock**

Sample set	Sepsis	Septic shock	P-value ^a
ICU-enterotype I	69 (65.1%)	20 (80%)	0.164
ICU-enterotype II	37 (34.9%)	5 (20%)	
APACHE II^b score ≤ 18			
ICU-enterotype I	30 (78.9%)	7 (70%)	0.675
ICU-enterotype II	8 (21.1%)	3 (30%)	
APACHE II^b score > 18			
ICU-enterotype I	39 (57.4%)	13 (86.7%)	0.041
ICU-enterotype II	29 (42.6%)	2 (13.3%)	

664 *Note:* ^aP-value was calculated using Fisher's exact test. ^bAPACHE II, acute physiology
665 and chronic health evaluation.

666

667 **Supplementary material**

668 **Supplementary figure legends**

669 **Figure S1 The distributions of 131 fecal samples from 64 ICU patients over** 670 **their first 9 days in ICU since admission**

671 Each of the rows represents a patient, and each of the columns represents the day. Day
672 1 also refers to the admission day. The last column represents the mortality observed
673 within 28 days. Only fecal samples at the site of colored circles were obtained and
674 analyzed to calculate enterotypes in this study. The circles represent the characteristics

of each patient at each day, whose color represents the ICU-enterotypes and shape (not filled or filled) represents the sepsis or septic shock.

677

Figure S2 Distributions of the log-transformed relative abundance of the most dominant genera in two ICU-enterotypes

The left panel displays the observed distributions using frequency distribution histogram with a density curve. The right panel shows these distributions in ICU-enterotype space. The solid circles refer to samples of septic shock, while the hollow circles refer to samples of sepsis. The most discriminating genera including *Bacteroides* (dominant in ICU-enterotype I, **A**) and *Enterococcus* (dominant in ICU-enterotype II, **B**), as well as their ratio (**C**) show obvious gradient distributions against PCo 1. Another unclassified genus of family *Enterobacteriaceae* (**D**), which is quite dominant in ICU-enterotype I shows obvious gradient distributions against PCo 2.

689

Figure S3 Distributions of antibiotic use before/after ICU admission, enema and infection sites of samples in ICU-enterotype space

The color and shape of circles are based on the ICU-enterotypes and characteristics including the types of antibiotics (**A** and **B**), the way of defecation (**C**), and the infection sites (**D**). In all plots, shaded ellipses represent the 80% confidence interval, while the dotted ellipse borders represent the 95% confidence interval. Boxes represent the interquartile range (IQR) between first and third quartiles and the line inside represents the median. Whiskers denote the lowest and highest values within $1.5 \times \text{IQR}$ from the first and third quartiles, respectively. Statistical significance was tested using the Mann–Whitney–Wilcoxon test, *** $P < 0.001$, n.s., not significant.

700

Figure S4 The comparison of the ability in the classification of ICU-enterotypes between the 10 individual taxonomic biomarkers and the MHI score

The receiver operating characteristic (ROC) curve with 95% confidence intervals and area under the curve (AUC) with 95% confidence intervals were generated for the 131

705 fecal samples using 9,999 stratified bootstrap replicates.

706

707 **Supplementary table legends**

708 **Table S1 The clinical parameters of 64 ICU patients**

709 **Table S2 The characteristics of 131 fecal samples**

710 **Table S3 The statistical evaluation of the number of clusters, based on JSD**
 711 **distance matrix at genus level using 131 fecal samples**

712 **Table S4 The comparisons of distributions of taxonomic composition between**
 713 **two ICU-enterotypes**

714 **Table S5 The comparisons of phenotypic characteristics of 64 patients between**
 715 **two ICU-enterotypes**

716 **Table S6 The correlations between taxonomic composition of first fecal samples**
 717 **of 64 patients and their corresponding clinical parameters**

718

A

Lac ≥ 2.5 mmol/L (15)Lac < 2.5 mmol/L (49)

Fisher's exact test
 $p = 0.007$

ICU-enterotype I (47)

ICU-enterotype II (17)

B